Forty consecutive patients ( 29 male , 11 female ; mean age , 61 + / -11 years ) with suspected coronary artery disease were randomized to 2 groups to receive 100 mL of either iopromide 370 ( group 1 : Ultravist 370 , 370 mg iodine/mL ; Schering AG , Berlin , Germany ) or iomeprol 400 ( group 2 : Iomeron 400 , 400 mg iodine/mL ; Bracco Imaging SpA , Milan , Italy ) .
